AT-1002 TFA is a tight junction regulator and absorption enhancer. It is a 6-mer synthetic peptide.

Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.) , shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.

AT-1002 is a tight junction regulator and absorption enhancer. It is a 6-mer synthetic peptide.

G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.

AT-1002 TFA, a 6-mer synthetic peptide, functions as a tight junction regulator and absorption enhancer.